Across clinical research on GLP-1 receptor agonists (Semaglutide, Tirzepatide, Retatrutide), the most frequently reported adverse effects are gastrointestinal: nausea, vomiting, diarrhea and constipation. These are typically dose-dependent and most common when starting or increasing a dose.
Clinical protocols raise the dose gradually precisely because GI effects cluster around dose increases. Jumping straight to a high dose tends to increase reported nausea — one reason "more is better" doesn't apply to incretin agonists.
Because the GI effects are additive and the mechanism overlaps, combining two GLP-1 agonists mostly adds side-effects without added benefit. Our stacking guide flags this as a combination to avoid; the productive pairing is a GLP-1 with an amylin analog (CagriSema), which engages a different pathway.
Higher-potency compounds (Tirzepatide, Retatrutide) can carry a heavier GI profile at comparable stages, which is part of the trade-off discussed in the fat-loss comparison.
These are research chemicals for laboratory use only. The information here summarizes published research for context and is not medical advice.
Published research most commonly reports gastrointestinal effects — nausea, vomiting, diarrhea and constipation — which are typically dose-dependent and most common when starting or increasing a dose.
Gastrointestinal effects cluster around dose increases, so clinical research protocols titrate the dose upward gradually to improve tolerability.
Combining two GLP-1 agonists is discouraged because the mechanism overlaps and gastrointestinal effects are additive with no added benefit. Pairing a GLP-1 with an amylin analog (CagriSema) uses a different pathway instead.